Copenhagen, Denmark, November 14, 2024 – MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announced the appointment of Veronica Gambillara Fonck as its new Chair of the Board of Directors. Gerd Zettlmeissl, the previous Chair, who was instrumental in the transition of MinervaX from a […]
Funding to support development of first-in-class CLDN1 targeted medicines Strong syndicate of international life science investors One of the largest ADC-focused private fundraisings globally in 2024 Copenhagen, Denmark, 12 November 2024 – Novo Holdings, a leading global life science investor, today announced that it has co-led a $181.4 million Series D financing in Alentis Therapeutics (“Alentis”). […]
STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types Gene expression data shows upregulation of innate immunity pathways Tumor regressions observed at all dose levels, 60-200 mg TIW 11 November 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat […]
– Complete 3-year clinical data from the MATCH Phase 2 study demonstrate long-term efficacy and safety with autologous, non-engineered macrophages in patients with advanced liver cirrhosis. – New preclinical data support superior anti-inflammatory and anti-fibrotic effect of RTX001, an engineered macrophage investigational therapy, compared to non-engineered macrophages. – RTX001 has recently entered into a Phase […]
Infinitopes’ lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, “off-the-shelf” cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancers Infinitopes’ proprietary vector delivery system reliably triggers durable T-cell protection, which halted or delayed tumour progression in industry standard preclinical mouse models, without checkpoint inhibitor […]
